2026 Interim Report
Filed with HKEX · Stock code 2595 · · 77 pages · English
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
- VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)
- Voluntary announcement proposed share repurchase on the market
Later from Genfleet Therapeutics (Shanghai)
- VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase
- Announcement pursuant to rule 13.10 of the listing rules
- VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276
- Resignation of non-executive director
- List of directors and their roles and functions
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)